Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.
1. A method of treating obesity and/or one or more sequelae thereof in a subject, comprising:
administering to a subject in need of treatment for obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition to enhance thermogenesis associated with brown fat or brown fat cells,
wherein said pharmaceutical composition is selected from the group consisting of a recombinant B-cell activating factor (BAFF) protein or an agonistic variant thereof.
2. The method of claim 1 , wherein thermogenesis associated with brown fat comprises thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof.
3. The method of claim 1 , wherein thermogenesis associated with brown fat or brown fat cells is enhanced by increasing the level or activity of BAFF.
4. The method of claim 1 , wherein said pharmaceutical composition is a recombinant BAFF protein.
5. The method of claim 1 , wherein said pharmaceutical composition is administered to a subject via parenteral, topical, oral, or local administration, injection, or a combination thereof.
6. The method of claim 5 , wherein said subject is a human in need of treatment for obesity and/or one or more sequelae thereof.
7. The method of claim 1 , wherein said pharmaceutical composition is an agonistic variant of a recombinant BAFF protein.